Enfortumab vedotin: observed
17 studies: patients on it are followed, or it is given outside a trial. Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial CarcinomaRecruitingNCT07870577Report a problem
- Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)RecruitingNCT07855926Report a problem
- Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational StudyEnrolling by invitationNCT07633353Report a problem
- Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line TreatmentNot yet recruitingNCT07545486Report a problem
- Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder CancerNot yet recruitingNCT07468838Report a problem
- International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUCNot yet recruitingNCT07420855Report a problem
- A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial CarcinomaRecruitingNCT07390617Report a problem
- Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial CarcinomaRecruitingNCT07339878Report a problem
- Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based TherapyNot yet recruitingNCT07072637Report a problem
- Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.RecruitingNCT06724159Report a problem
- Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial CarcinomaRecruitingNCT06657157Report a problem
- Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric AssessmentsRecruitingNCT06138561Report a problem
- A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV InjectionRecruitingNCT06011954Report a problem
- A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial CarcinomaActive, not recruitingNCT07063758Report a problem
- Association Between Drug-related Cutaneous Adverse Events and Progression Free Survival in Patients Treated with Enfortumab VedotinCompletedNCT06682845Report a problem
- Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related ToxicitiesCompletedNCT05349383Report a problem
- An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial CarcinomaApproved for marketingNCT04136808Report a problem